Viridian Therapeutics, Inc. (VRDN)
After hours:
| Previous close | 12.70 |
| Open | 12.74 |
| Bid | 12.85 x 200 |
| Ask | 12.89 x 200 |
| Day's range | 12.43 - 13.06 |
| 52-week range | 10.93 - 28.99 |
| Volume | |
| Avg. volume | 895,446 |
| Market cap | 808.447M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.31 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.27 |
Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 04, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to th
Business WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
Simply Wall St.Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
Viridian Therapeutics ( NASDAQ:VRDN ) Full Year 2023 Results Key Financial Results Net loss: US$237.7m (loss widened by...
